Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis.

European journal of gastroenterology & hepatology - 1 Jul 2017

Zheng Yi-Xiang, Zhou Peng-Cheng, Zhou Rong-Rong, Fan Xue-Gong

Abstract excerpt

BACKGROUND AND AIM: Besides regulating lipid metabolism, statins have garnered considerable interest because of their antiviral and antineoplastic properties. The potential benefit of statins using in chronic hepatitis C (CHC) patients is not well described. This meta-analysis was carried out to quantitatively assess the efficacy of statins in improving the therapeutic effect and prognosis of patients with CHC....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Hepatocellular
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C, Chronic

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Liver Cirrhosis

Share to Liver Neoplasms

Share to Protective Factors

Share to Sustained Virologic Response

Source

Identifiers

PMID: 28240613
DOI: 10.1097/MEG.0000000000000867

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The benefit of statins in chronic hepatitis C patients: a systematic review and meta-analysis.PMID 28240613Read ↗

Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis.Semantic proximity Read ↗

Sustained virologic response and other potential genotype-specific roles of statins among patients with hepatitis C-related chronic liver diseases.Semantic proximity Read ↗

An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin.Semantic proximity Read ↗

The role of statins as therapeutic agents in cancerSemantic proximity Read ↗

Impact of added fluvastatin to standard-of-care treatment on sustained virological response in naïve chronic hepatitis C Patients infected with genotypes 1 and 3.Semantic proximity Read ↗

Liver and Statins: A Critical Appraisal of the Evidence.Semantic proximity Read ↗

Treatment with peginterferon plus ribavirin vs. interferon plus ribavirin for 48 weeks in Chinese patients with chronic hepatitis C.Semantic proximity Read ↗

Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.Semantic proximity Read ↗

The Synergistic Effect of Fluvastatin and IFN-λ on Peripheral Blood Mononuclear Cells of Chronic Hepatitis C Virus (HCV) Patients with IL-28B rs12979860 CC Genotype.Semantic proximity Read ↗

Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C.Semantic proximity Read ↗

Statins are potential anticancerous agents (Review)Semantic proximity Read ↗

Metabolic and cardiovascular complications after virological cure in hepatitis C: What awaits beyond.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.